Paion

DE: PA8

€140.5m market cap

€2.2 last close

PAION is a specialty pharma company developing anaesthesia products. Its lead product, remimazolam, is partnered with Mundipharma in Japan, Yichang in China, Hana Pharma in S Korea, Cosmo in the US, Pendopharm in Canada and R-Pharm in CIS, Turkey and MENA.

Investment summary

Paion is moving closer to commercialisation of remimazolam, its ultra-short-acting IV sedative/anaesthetic that combines the best features of approved agents midazolam and propofol. Partner Yichang Humanwell filed for approval of remimazolam in procedural sedation in China in November, and Mundipharma filed for approval in general anaesthesia (GA) in Japan in December. Cosmo filed for US approval in April, after Paion successfully completed clinical development in procedural sedation. R-Pharm plans to file for approval in GA in Russia by end 2019. The primary target in the US is to replace midazolam as the sedative of choice for procedures such as colonoscopy and bronchoscopy; faster induction and recovery with remimazolam reduces total procedure time and should increase throughput. Paion has initiated a Phase III in GA in Europe; full recruitment expected by the end of 2019. Cash of €17.2m at 31 December plus €7.5m in milestones for the US filing is sufficient to report top-line data from the European Phase III.

Y/E Dec
Revenue (€m)
EBITDA (€m)
PBT (€m)
EPS (c)
P/E (x)
P/CF (x)
2017A 5.8 (15.9) (15.9) (20.5) N/A N/A
2018A 2.8 (12.5) (12.4) (15.9) N/A N/A
2019E 10.5 (8.6) (8.6) (9.3) N/A N/A
2020E 20.0 5.8 5.8 11.8 18.8 24.4
Last updated on 17/04/2019
Industry outlook

Remimazolam has important advantages over competing products, including fast onset and offset of action with lower risk of cardiopulmonary events than the standard-of-care midazolam and propofol, and a reversal agent exists if there is over sedation.

Last updated on 17/04/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (€m) 18.7
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 0.9 (6.6) (2.4)
Relative* (6.9) (15.6) (0.6)
52-week high/low €2.6/€2.0
*% relative to local index
Key management
Jörg Spiekerkötter, Chairman
Wolfgang Soehngen CEO
Abdelghani Omari CFO

Content on Paion